{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:14:17Z","timestamp":1793830457956,"version":"4.6.1"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T00:00:00Z","timestamp":1725321600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T00:00:00Z","timestamp":1725321600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Jpn J Radiol"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Recognition of the importance of prostate-specific membrane antigen (PSMA) PET\/CT in the diagnosis of prostate cancer has steadily increased following the publication of extensive data on its diagnostic accuracy and impact on patient management over the past decade. Several recent clinical trials and investigations regarding PSMA PET\/CT have been ongoing in our country, and this examination is expected to become increasingly widespread in the future. This review explains the characteristics of PSMA PET\/CT, its diagnostic capabilities and superiority over other modalities, the three proposed PSMA PET\/CT interpretation criteria (the European Association of Nuclear Medicine [EANM], the Prostate Cancer Molecular Imaging Standardized Evaluation [PROMISE], and the PSMA Reporting and Data System [PSMA-RADS]), and the application of PSMA PET\/CT to prostate cancer treatment (improvement of local control, irradiation of oligometastases, and salvage radiotherapy), incorporating actual clinical images and the latest findings.<\/jats:p>","DOI":"10.1007\/s11604-024-01646-9","type":"journal-article","created":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T04:02:21Z","timestamp":1725336141000},"page":"1-12","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["PSMA PET\/CT imaging and its application to prostate cancer treatment"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4442-226X","authenticated-orcid":false,"given":"Tomoaki","family":"Otani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryusuke","family":"Nakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeaki","family":"Umeoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Nakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,3]]},"reference":[{"issue":"1","key":"1646_CR1","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.eururo.2019.08.005","volume":"77","author":"MB Culp","year":"2020","unstructured":"Culp MB, Soerjomataram I, Efstathiou JA, Bray F, Jemal A. Recent global patterns in prostate cancer incidence and mortality rates. Eur Urol. 2020;77(1):38\u201352.","journal-title":"Eur Urol"},{"issue":"1","key":"1646_CR2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17\u201348.","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"1646_CR3","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.eururo.2020.09.041","volume":"79","author":"MB Cook","year":"2021","unstructured":"Cook MB, Hurwitz LM, Geczik AM, Butler EN. An up-to-date assessment of US prostate cancer incidence rates by stage and race: a novel approach combining multiple imputation with age and delay adjustment. Eur Urol. 2021;79(1):33\u201341.","journal-title":"Eur Urol"},{"key":"1646_CR4","unstructured":"Cancer Statistics. https:\/\/ganjoho.jp\/reg_stat\/index.html"},{"issue":"10","key":"1646_CR5","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.6004\/jnccn.2023.0050","volume":"21","author":"EM Schaeffer","year":"2023","unstructured":"Schaeffer EM, Srinivas S, Adra N, An Y, Barocas D, Bitting R, et al. Prostate cancer, version 4.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2023;21(10):1067\u201396.","journal-title":"J Natl Compr Canc Netw"},{"issue":"11","key":"1646_CR6","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1001\/jama.280.11.969","volume":"280","author":"AV D'Amico","year":"1998","unstructured":"D\u2019Amico AV, Whittington R, Malkowicz SB, Schultz D, Blank K, Broderick GA, et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA. 1998;280(11):969\u201374.","journal-title":"JAMA"},{"issue":"10","key":"1646_CR7","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1007\/s10147-019-01478-y","volume":"24","author":"R Aizawa","year":"2019","unstructured":"Aizawa R, Takayama K, Nakamura K, Inoue T, Yamasaki T, Kobayashi T, et al. Ten-year outcomes of high-dose intensity-modulated radiation therapy for nonmetastatic prostate cancer with unfavorable risk: early initiation of salvage therapy may replace long-term adjuvant androgen deprivation. Int J Clin Oncol. 2019;24(10):1247\u201355.","journal-title":"Int J Clin Oncol"},{"issue":"4","key":"1646_CR8","doi-asserted-by":"publisher","first-page":"163.e7","DOI":"10.1016\/j.urolonc.2014.11.018","volume":"33","author":"A Briganti","year":"2015","unstructured":"Briganti A, Karnes RJ, Gandaglia G, Spahn M, Gontero P, Tosco L, et al. Natural history of surgically treated high-risk prostate cancer. Urol Oncol. 2015;33(4):163.e7-13.","journal-title":"Urol Oncol"},{"issue":"1","key":"1646_CR9","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1158\/1078-0432.CCR-15-0820","volume":"22","author":"U Haberkorn","year":"2016","unstructured":"Haberkorn U, Eder M, Kopka K, Babich JW, Eisenhut M. New strategies in prostate cancer: prostate-specific membrane antigen (PSMA) ligands for diagnosis and therapy. Clin Cancer Res. 2016;22(1):9\u201315.","journal-title":"Clin Cancer Res"},{"issue":"Suppl 10","key":"1646_CR10","first-page":"S13","volume":"6","author":"SS Chang","year":"2004","unstructured":"Chang SS. Overview of prostate-specific membrane antigen. Rev Urol. 2004;6(Suppl 10):S13-8.","journal-title":"Rev Urol"},{"issue":"4","key":"1646_CR11","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1016\/j.eururo.2016.08.003","volume":"71","author":"N Mottet","year":"2017","unstructured":"Mottet N, Bellmunt J, Bolla M, Briers E, Cumberbatch MG, De Santis M, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol. 2017;71(4):618\u201329.","journal-title":"Eur Urol"},{"issue":"4","key":"1646_CR12","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.eururo.2016.08.002","volume":"71","author":"P Cornford","year":"2017","unstructured":"Cornford P, Bellmunt J, Bolla M, Briers E, De Santis M, Gross T, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol. 2017;71(4):630\u201342.","journal-title":"Eur Urol"},{"issue":"8","key":"1646_CR13","doi-asserted-by":"publisher","first-page":"713","DOI":"10.3390\/ph14080713","volume":"14","author":"U Hennrich","year":"2021","unstructured":"Hennrich U, Eder M. [(68)Ga]Ga-PSMA-11: the first FDA-approved (68)Ga-radiopharmaceutical for PET imaging of prostate cancer. Pharmaceuticals (Basel). 2021;14(8):713.","journal-title":"Pharmaceuticals (Basel)"},{"issue":"4","key":"1646_CR14","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1021\/bc200279b","volume":"23","author":"M Eder","year":"2012","unstructured":"Eder M, Sch\u00e4fer M, Bauder-W\u00fcst U, Hull WE, W\u00e4ngler C, Mier W, et al. 68Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjug Chem. 2012;23(4):688\u201397.","journal-title":"Bioconjug Chem"},{"issue":"4","key":"1646_CR15","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s12149-021-01602-x","volume":"35","author":"T Watabe","year":"2021","unstructured":"Watabe T, Uemura M, Soeda F, Naka S, Ujike T, Hatano K, et al. High detection rate in [(18)F]PSMA-1007 PET: interim results focusing on biochemical recurrence in prostate cancer patients. Ann Nucl Med. 2021;35(4):523\u20138.","journal-title":"Ann Nucl Med"},{"issue":"12","key":"1646_CR16","doi-asserted-by":"publisher","first-page":"1978","DOI":"10.2967\/jnumed.116.175810","volume":"57","author":"N Harada","year":"2016","unstructured":"Harada N, Kimura H, Onoe S, Watanabe H, Matsuoka D, Arimitsu K, et al. Synthesis and biologic evaluation of novel 18F-labeled probes targeting prostate-specific membrane antigen for PET of prostate cancer. J Nucl Med. 2016;57(12):1978\u201384.","journal-title":"J Nucl Med"},{"issue":"2","key":"1646_CR17","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1111\/cas.13911","volume":"110","author":"T Saga","year":"2019","unstructured":"Saga T, Nakamoto Y, Ishimori T, Inoue T, Shimizu Y, Kimura H, et al. Initial evaluation of PET\/CT with (18) F-FSU-880 targeting prostate-specific membrane antigen in prostate cancer patients. Cancer Sci. 2019;110(2):742\u201350.","journal-title":"Cancer Sci"},{"issue":"2","key":"1646_CR18","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.juro.2006.10.097","volume":"177","author":"MS Cookson","year":"2007","unstructured":"Cookson MS, Aus G, Burnett AL, Canby-Hagino ED, D\u2019Amico AV, Dmochowski RR, et al. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer update panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol. 2007;177(2):540\u20135.","journal-title":"J Urol"},{"issue":"4","key":"1646_CR19","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1016\/j.ijrobp.2006.04.029","volume":"65","author":"M Roach 3rd","year":"2006","unstructured":"Roach M 3rd, Hanks G, Thames H Jr, Schellhammer P, Shipley WU, Sokol GH, et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys. 2006;65(4):965\u201374.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"1646_CR20","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1007\/s10147-019-01596-7","volume":"25","author":"R Aizawa","year":"2020","unstructured":"Aizawa R, Takayama K, Nakamura K, Inoue T, Yamasaki T, Kobayashi T, et al. Low incidence of late recurrence in patients with intermediate-risk prostate cancer treated by intensity-modulated radiation therapy plus short-term androgen deprivation therapy. Int J Clin Oncol. 2020;25(4):713\u20139.","journal-title":"Int J Clin Oncol"},{"issue":"9","key":"1646_CR21","doi-asserted-by":"publisher","first-page":"2925","DOI":"10.1007\/s00259-021-05189-3","volume":"48","author":"A Afshar-Oromieh","year":"2021","unstructured":"Afshar-Oromieh A, da Cunha ML, Wagner J, Haberkorn U, Debus N, Weber W, et al. Performance of [(68)Ga]Ga-PSMA-11 PET\/CT in patients with recurrent prostate cancer after prostatectomy-a multi-centre evaluation of 2533 patients. Eur J Nucl Med Mol Imaging. 2021;48(9):2925\u201334.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"1646_CR22","doi-asserted-by":"publisher","first-page":"881","DOI":"10.2967\/jnumed.119.234799","volume":"61","author":"E Mena","year":"2020","unstructured":"Mena E, Lindenberg ML, Turkbey IB, Shih JH, Harmon SA, Lim I, et al. (18)F-DCFPyL PET\/CT imaging in patients with biochemically recurrent prostate cancer after primary local therapy. J Nucl Med. 2020;61(6):881\u20139.","journal-title":"J Nucl Med"},{"issue":"3","key":"1646_CR23","doi-asserted-by":"publisher","first-page":"362","DOI":"10.2967\/jnumed.118.212233","volume":"60","author":"FL Giesel","year":"2019","unstructured":"Giesel FL, Knorr K, Spohn F, Will L, Maurer T, Flechsig P, et al. Detection efficacy of (18)F-PSMA-1007 PET\/CT in 251 patients with biochemical recurrence of prostate cancer after radical prostatectomy. J Nucl Med. 2019;60(3):362\u20138.","journal-title":"J Nucl Med"},{"issue":"12","key":"1646_CR24","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1007\/s00259-018-4089-x","volume":"45","author":"K Rahbar","year":"2018","unstructured":"Rahbar K, Afshar-Oromieh A, Seifert R, Wagner S, Sch\u00e4fers M, B\u00f6gemann M, et al. Diagnostic performance of (18)F-PSMA-1007 PET\/CT in patients with biochemical recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2018;45(12):2055\u201361.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"9","key":"1646_CR25","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.1007\/s00259-019-04385-6","volume":"46","author":"M Wondergem","year":"2019","unstructured":"Wondergem M, Jansen BHE, van der Zant FM, van der Sluis TM, Knol RJJ, van Kalmthout LWM, et al. Early lesion detection with (18)F-DCFPyL PET\/CT in 248 patients with biochemically recurrent prostate cancer. Eur J Nucl Med Mol Imaging. 2019;46(9):1911\u20138.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"1646_CR26","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.7150\/thno.18421","volume":"7","author":"CA Jilg","year":"2017","unstructured":"Jilg CA, Drendel V, Rischke HC, Beck T, Vach W, Schaal K, et al. Diagnostic accuracy of Ga-68-HBED-CC-PSMA-ligand-PET\/CT before salvage lymph node dissection for recurrent prostate cancer. Theranostics. 2017;7(6):1770\u201380.","journal-title":"Theranostics"},{"issue":"3","key":"1646_CR27","doi-asserted-by":"publisher","first-page":"223","DOI":"10.4274\/mirt.galenos.2021.41033","volume":"31","author":"G M\u00fctevelizade","year":"2022","unstructured":"M\u00fctevelizade G, Sezgin C, G\u00fcm\u00fc\u015fer G, Sayit E. Unexpected metastatic localizations of prostate cancer determined by (68)Ga PSMA PET\/CT: series of four cases. Mol Imaging Radionucl Ther. 2022;31(3):223\u20136.","journal-title":"Mol Imaging Radionucl Ther"},{"issue":"1","key":"1646_CR28","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1590\/s1677-5538.ibju.2017.0071","volume":"44","author":"LGM Valle","year":"2018","unstructured":"Valle LGM, Rahal A Jr, Falsarella PM, de Andrade JR, Smaletz O, Osawa A, et al. Prostate cancer recurrence in vas deferens - fusion image guide as an important tool in dignosis. Int Braz J Urol. 2018;44(1):192\u20135.","journal-title":"Int Braz J Urol"},{"issue":"3","key":"1646_CR29","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1007\/s12149-021-01704-6","volume":"36","author":"T Otani","year":"2022","unstructured":"Otani T, Saga T, Ishimori T, Kidera E, Shimizu Y, Aizawa R, et al. Detection efficacy of PET\/CT with (18)F-FSU-880 in patients with suspected recurrent prostate cancer: a prospective single-center study. Ann Nucl Med. 2022;36(3):302\u20139.","journal-title":"Ann Nucl Med"},{"issue":"12","key":"1646_CR30","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.2967\/jnumed.120.242180","volume":"61","author":"WP Fendler","year":"2020","unstructured":"Fendler WP, Ferdinandus J, Czernin J, Eiber M, Flavell RR, Behr SC, et al. Impact of (68)Ga-PSMA-11 PET on the management of recurrent prostate cancer in a prospective single-arm clinical trial. J Nucl Med. 2020;61(12):1793\u20139.","journal-title":"J Nucl Med"},{"issue":"13","key":"1646_CR31","doi-asserted-by":"publisher","first-page":"3674","DOI":"10.1158\/1078-0432.CCR-20-4573","volume":"27","author":"MJ Morris","year":"2021","unstructured":"Morris MJ, Rowe SP, Gorin MA, Saperstein L, Pouliot F, Josephson D, et al. Diagnostic performance of (18)F-DCFPyL-PET\/CT in men with biochemically recurrent prostate cancer: results from the CONDOR phase III, multicenter study. Clin Cancer Res. 2021;27(13):3674\u201382.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"1646_CR32","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/j.jmir.2023.04.005","volume":"54","author":"H Daniels","year":"2023","unstructured":"Daniels H, Gilbert R, Bonin L. The diagnostic accuracy of (68)Ga-PSMA PET\/CT versus (99m)Tc-MDP bone scintigraphy for identifying bone metastases in persons with prostate cancer: a systematic review. J Med Imaging Radiat Sci. 2023;54(3):545\u201355.","journal-title":"J Med Imaging Radiat Sci"},{"issue":"3","key":"1646_CR33","doi-asserted-by":"publisher","first-page":"386","DOI":"10.2214\/AJR.21.27323","volume":"219","author":"G Zhao","year":"2022","unstructured":"Zhao G, Ji B. Head-to-head comparison of (68)Ga-PSMA-11 PET\/CT and (99m)Tc-MDP bone scintigraphy for the detection of bone metastases in patients with prostate cancer: a meta-analysis. AJR Am J Roentgenol. 2022;219(3):386\u201395.","journal-title":"AJR Am J Roentgenol"},{"issue":"7","key":"1646_CR34","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1007\/s12149-020-01474-7","volume":"34","author":"DH Simsek","year":"2020","unstructured":"Simsek DH, Sanli Y, Civan C, Engin MN, Isik EG, Ozkan ZG, et al. Does bone scintigraphy still have a role in the era of 68 Ga-PSMA PET\/CT in prostate cancer? Ann Nucl Med. 2020;34(7):476\u201385.","journal-title":"Ann Nucl Med"},{"issue":"3","key":"1646_CR35","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/j.eururo.2019.02.033","volume":"76","author":"B Turkbey","year":"2019","unstructured":"Turkbey B, Rosenkrantz AB, Haider MA, Padhani AR, Villeirs G, Macura KJ, et al. Prostate imaging reporting and data system version 2.1: 2019 update of prostate imaging reporting and data system version 2. Eur Urol. 2019;76(3):340\u201351.","journal-title":"Eur Urol"},{"issue":"6","key":"1646_CR36","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.eururo.2021.08.002","volume":"80","author":"L Emmett","year":"2021","unstructured":"Emmett L, Buteau J, Papa N, Moon D, Thompson J, Roberts MJ, et al. The additive diagnostic value of prostate-specific membrane antigen positron emission tomography computed tomography to multiparametric magnetic resonance imaging triage in the diagnosis of prostate cancer (PRIMARY): a prospective multicentre study. Eur Urol. 2021;80(6):682\u20139.","journal-title":"Eur Urol"},{"issue":"11","key":"1646_CR37","first-page":"1644","volume":"63","author":"L Emmett","year":"2022","unstructured":"Emmett L, Papa N, Buteau J, Ho B, Liu V, Roberts M, et al. The PRIMARY score: using intraprostatic (68)Ga-PSMA PET\/CT patterns to optimize prostate cancer diagnosis. J Nucl Med. 2022;63(11):1644\u201350.","journal-title":"J Nucl Med"},{"issue":"4","key":"1646_CR38","doi-asserted-by":"publisher","first-page":"e291","DOI":"10.1097\/RLU.0000000000002473","volume":"44","author":"DA Ferraro","year":"2019","unstructured":"Ferraro DA, Rupp NJ, Donati OF, Messerli M, Eberli D, Burger IA. 68Ga-PSMA-11 PET\/MR can be false positive in normal prostatic tissue. Clin Nucl Med. 2019;44(4):e291\u20133.","journal-title":"Clin Nucl Med"},{"issue":"3","key":"1646_CR39","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1148\/radiol.2018180788","volume":"289","author":"RM Hicks","year":"2018","unstructured":"Hicks RM, Simko JP, Westphalen AC, Nguyen HG, Greene KL, Zhang L, et al. Diagnostic accuracy of (68)Ga-PSMA-11 PET\/MRI compared with multiparametric MRI in the detection of prostate cancer. Radiology. 2018;289(3):730\u20137.","journal-title":"Radiology"},{"issue":"5","key":"1646_CR40","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.eururo.2015.12.053","volume":"70","author":"M Eiber","year":"2016","unstructured":"Eiber M, Weirich G, Holzapfel K, Souvatzoglou M, Haller B, Rauscher I, et al. Simultaneous (68)Ga-PSMA HBED-CC PET\/MRI improves the localization of primary prostate cancer. Eur Urol. 2016;70(5):829\u201336.","journal-title":"Eur Urol"},{"issue":"2","key":"1646_CR41","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1148\/radiol.2018172232","volume":"288","author":"SY Park","year":"2018","unstructured":"Park SY, Zacharias C, Harrison C, Fan RE, Kunder C, Hatami N, et al. Gallium 68 PSMA-11 PET\/MR imaging in patients with intermediate- or high-risk prostate cancer. Radiology. 2018;288(2):495\u2013505.","journal-title":"Radiology"},{"issue":"1","key":"1646_CR42","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1007\/s00259-016-3490-6","volume":"44","author":"J Schwenck","year":"2017","unstructured":"Schwenck J, Rempp H, Reischl G, Kruck S, Stenzl A, Nikolaou K, et al. Comparison of (68)Ga-labelled PSMA-11 and (11)C-choline in the detection of prostate cancer metastases by PET\/CT. Eur J Nucl Med Mol Imaging. 2017;44(1):92\u2013101.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"1646_CR43","doi-asserted-by":"publisher","DOI":"10.1186\/s41824-018-0027-1","author":"O Alonso","year":"2018","unstructured":"Alonso O, Dos Santos G, Garc\u00eda Fontes M, Balter H, Engler H. (68)Ga-PSMA and (11)C-Choline comparison using a tri-modality PET\/CT-MRI (3.0\u00a0T) system with a dedicated shuttle. Eur J Hybrid Imaging. 2018. https:\/\/doi.org\/10.1186\/s41824-018-0027-1.","journal-title":"Eur J Hybrid Imaging"},{"issue":"10","key":"1646_CR44","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1007\/s00259-017-3725-1","volume":"44","author":"S Fanti","year":"2017","unstructured":"Fanti S, Minozzi S, Morigi JJ, Giesel F, Ceci F, Uprimny C, et al. Development of standardized image interpretation for 68Ga-PSMA PET\/CT to detect prostate cancer recurrent lesions. Eur J Nucl Med Mol Imaging. 2017;44(10):1622\u201335.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"1646_CR45","doi-asserted-by":"publisher","first-page":"469","DOI":"10.2967\/jnumed.117.198119","volume":"59","author":"M Eiber","year":"2018","unstructured":"Eiber M, Herrmann K, Calais J, Hadaschik B, Giesel FL, Hartenbach M, et al. Prostate cancer molecular imaging standardized evaluation (PROMISE): proposed miTNM classification for the interpretation of PSMA-ligand PET\/CT. J Nucl Med. 2018;59(3):469\u201378.","journal-title":"J Nucl Med"},{"issue":"5","key":"1646_CR46","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.eururo.2023.02.002","volume":"83","author":"R Seifert","year":"2023","unstructured":"Seifert R, Emmett L, Rowe SP, Herrmann K, Hadaschik B, Calais J, et al. Second version of the prostate cancer molecular imaging standardized evaluation framework including response evaluation for clinical trials (PROMISE V2). Eur Urol. 2023;83(5):405\u201312.","journal-title":"Eur Urol"},{"issue":"3","key":"1646_CR47","doi-asserted-by":"publisher","first-page":"479","DOI":"10.2967\/jnumed.117.195255","volume":"59","author":"SP Rowe","year":"2018","unstructured":"Rowe SP, Pienta KJ, Pomper MG, Gorin MA. Proposal for a structured reporting system for prostate-specific membrane antigen-targeted PET imaging: PSMA-RADS version 1.0. J Nucl Med. 2018;59(3):479\u201385.","journal-title":"J Nucl Med"},{"issue":"4","key":"1646_CR48","doi-asserted-by":"publisher","first-page":"533","DOI":"10.2967\/jnumed.119.232504","volume":"61","author":"A Toriihara","year":"2020","unstructured":"Toriihara A, Nobashi T, Baratto L, Duan H, Moradi F, Park S, et al. Comparison of 3 interpretation criteria for (68)Ga-PSMA11 PET based on inter- and intrareader agreement. J Nucl Med. 2020;61(4):533\u20139.","journal-title":"J Nucl Med"},{"issue":"1","key":"1646_CR49","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.ijrobp.2007.03.065","volume":"69","author":"D Pucar","year":"2007","unstructured":"Pucar D, Hricak H, Shukla-Dave A, Kuroiwa K, Drobnjak M, Eastham J, et al. Clinically significant prostate cancer local recurrence after radiation therapy occurs at the site of primary tumor: magnetic resonance imaging and step-section pathology evidence. Int J Radiat Oncol Biol Phys. 2007;69(1):62\u20139.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"1646_CR50","doi-asserted-by":"publisher","first-page":"e787","DOI":"10.1016\/j.ijrobp.2011.11.030","volume":"82","author":"E Arrayeh","year":"2012","unstructured":"Arrayeh E, Westphalen AC, Kurhanewicz J, Roach M 3rd, Jung AJ, Carroll PR, et al. Does local recurrence of prostate cancer after radiation therapy occur at the site of primary tumor? Results of a longitudinal MRI and MRSI study. Int J Radiat Oncol Biol Phys. 2012;82(5):e787\u201393.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"1646_CR51","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/S0360-3016(02)02795-5","volume":"53","author":"N Cellini","year":"2002","unstructured":"Cellini N, Morganti AG, Mattiucci GC, Valentini V, Leone M, Luzi S, et al. Analysis of intraprostatic failures in patients treated with hormonal therapy and radiotherapy: implications for conformal therapy planning. Int J Radiat Oncol Biol Phys. 2002;53(3):595\u20139.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"1646_CR52","doi-asserted-by":"publisher","first-page":"101489","DOI":"10.1016\/j.adro.2024.101489","volume":"9","author":"R Aizawa","year":"2024","unstructured":"Aizawa R, Otani T, Ogata T, Moribata Y, Kido A, Akamatsu S, et al. Spatial pattern of intraprostatic recurrence after definitive external-beam radiation therapy for prostate cancer: implications for focal boost to intraprostatic dominant lesion. Adv Radiat Oncol. 2024;9(6):101489.","journal-title":"Adv Radiat Oncol"},{"issue":"3","key":"1646_CR53","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.prnil.2018.03.005","volume":"6","author":"T Feutren","year":"2018","unstructured":"Feutren T, Herrera FG. Prostate irradiation with focal dose escalation to the intraprostatic dominant nodule: a systematic review. Prostate Int. 2018;6(3):75\u201387.","journal-title":"Prostate Int"},{"issue":"7","key":"1646_CR54","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1200\/JCO.20.02873","volume":"39","author":"LGW Kerkmeijer","year":"2021","unstructured":"Kerkmeijer LGW, Groen VH, Pos FJ, Haustermans K, Monninkhof EM, Smeenk RJ, et al. Focal boost to the intraprostatic tumor in external beam radiotherapy for patients with localized prostate cancer: results from the FLAME randomized phase III trial. J Clin Oncol. 2021;39(7):787\u201396.","journal-title":"J Clin Oncol"},{"issue":"1","key":"1646_CR55","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.ijrobp.2011.10.069","volume":"84","author":"CR King","year":"2012","unstructured":"King CR. The timing of salvage radiotherapy after radical prostatectomy: a systematic review. Int J Radiat Oncol Biol Phys. 2012;84(1):104\u201311.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"9","key":"1646_CR56","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1111\/iju.13380","volume":"24","author":"Y Kakehi","year":"2017","unstructured":"Kakehi Y, Sugimoto M, Taoka R. Evidenced-based clinical practice guideline for prostate cancer (summary: Japanese Urological Association, 2016 edition). Int J Urol. 2017;24(9):648\u201366.","journal-title":"Int J Urol"},{"issue":"2","key":"1646_CR57","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.radonc.2011.10.024","volume":"103","author":"A Siegmann","year":"2012","unstructured":"Siegmann A, Bottke D, Faehndrich J, Brachert M, Lohm G, Miller K, et al. Salvage radiotherapy after prostatectomy - what is the best time to treat? Radiother Oncol. 2012;103(2):239\u201343.","journal-title":"Radiother Oncol"},{"issue":"15","key":"1646_CR58","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1200\/JCO.2006.08.9607","volume":"25","author":"AJ Stephenson","year":"2007","unstructured":"Stephenson AJ, Scardino PT, Kattan MW, Pisansky TM, Slawin KM, Klein EA, et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol. 2007;25(15):2035\u201341.","journal-title":"J Clin Oncol"},{"issue":"5","key":"1646_CR59","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1111\/bju.13397","volume":"117","author":"PJ van Leeuwen","year":"2016","unstructured":"van Leeuwen PJ, Stricker P, Hruby G, Kneebone A, Ting F, Thompson B, et al. (68) Ga-PSMA has a high detection rate of prostate cancer recurrence outside the prostatic fossa in patients being considered for salvage radiation treatment. BJU Int. 2016;117(5):732\u20139.","journal-title":"BJU Int"},{"issue":"2","key":"1646_CR60","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.euo.2022.01.001","volume":"5","author":"D Meijer","year":"2022","unstructured":"Meijer D, Eppinga WSC, Mohede RM, Vanneste BGL, Meijnen P, Meijer OWM, et al. Prostate-specific membrane antigen positron emission tomography\/computed tomography is associated with improved oncological outcome in men treated with salvage radiation therapy for biochemically recurrent prostate cancer. Eur Urol Oncol. 2022;5(2):146\u201352.","journal-title":"Eur Urol Oncol"},{"issue":"1","key":"1646_CR61","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1200\/JCO.1995.13.1.8","volume":"13","author":"S Hellman","year":"1995","unstructured":"Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995;13(1):8\u201310.","journal-title":"J Clin Oncol"},{"issue":"3","key":"1646_CR62","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1159\/000282653","volume":"53","author":"G Waaler","year":"1994","unstructured":"Waaler G, Nilssen MO. Prognostic factors in disseminated prostatic cancer, with special emphasis on extent of disease. Urol Int. 1994;53(3):130\u20134.","journal-title":"Urol Int"},{"issue":"2","key":"1646_CR63","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.euo.2018.09.005","volume":"2","author":"A Battaglia","year":"2019","unstructured":"Battaglia A, De Meerleer G, Tosco L, Moris L, Van den Broeck T, Devos G, et al. Novel insights into the management of oligometastatic prostate cancer: a comprehensive review. Eur Urol Oncol. 2019;2(2):174\u201388.","journal-title":"Eur Urol Oncol"},{"issue":"5","key":"1646_CR64","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","volume":"6","author":"R Phillips","year":"2020","unstructured":"Phillips R, Shi WY, Deek M, Radwan N, Lim SJ, Antonarakis ES, et al. Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial. JAMA Oncol. 2020;6(5):650\u20139.","journal-title":"JAMA Oncol"},{"issue":"5","key":"1646_CR65","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1200\/JCO.2017.75.4853","volume":"36","author":"P Ost","year":"2018","unstructured":"Ost P, Reynders D, Decaestecker K, Fonteyne V, Lumen N, De Bruycker A, et al. Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial. J Clin Oncol. 2018;36(5):446\u201353.","journal-title":"J Clin Oncol"},{"issue":"4","key":"1646_CR66","doi-asserted-by":"publisher","first-page":"546","DOI":"10.2967\/jnumed.119.231654","volume":"61","author":"H Song","year":"2020","unstructured":"Song H, Harrison C, Duan H, Guja K, Hatami N, Franc BL, et al. Prospective evaluation of (18)F-DCFPyL PET\/CT in biochemically recurrent prostate cancer in an academic center: a focus on disease localization and changes in management. J Nucl Med. 2020;61(4):546\u201351.","journal-title":"J Nucl Med"},{"issue":"8","key":"1646_CR67","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1007\/s00259-017-3711-7","volume":"44","author":"A Afshar-Oromieh","year":"2017","unstructured":"Afshar-Oromieh A, Holland-Letz T, Giesel FL, Kratochwil C, Mier W, Haufe S, et al. Diagnostic performance of (68)Ga-PSMA-11 (HBED-CC) PET\/CT in patients with recurrent prostate cancer: evaluation in 1007 patients. Eur J Nucl Med Mol Imaging. 2017;44(8):1258\u201368.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"9","key":"1646_CR68","doi-asserted-by":"publisher","first-page":"2970","DOI":"10.1007\/s00259-021-05221-6","volume":"48","author":"R Chen","year":"2021","unstructured":"Chen R, Wang Y, Shi Y, Zhu Y, Xu L, Huang G, et al. Diagnostic value of (18)F-FDG PET\/CT in patients with biochemical recurrent prostate cancer and negative (68)Ga-PSMA PET\/CT. Eur J Nucl Med Mol Imaging. 2021;48(9):2970\u20137.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"1646_CR69","doi-asserted-by":"publisher","first-page":"e65","DOI":"10.1016\/j.clgc.2016.09.002","volume":"15","author":"JJ Tosoian","year":"2017","unstructured":"Tosoian JJ, Gorin MA, Rowe SP, Andreas D, Szabo Z, Pienta KJ, et al. Correlation of PSMA-targeted (18)F-DCFPyL PET\/CT findings with immunohistochemical and genomic data in a patient with metastatic neuroendocrine prostate cancer. Clin Genitourin Cancer. 2017;15(1):e65\u20138.","journal-title":"Clin Genitourin Cancer"},{"issue":"11","key":"1646_CR70","doi-asserted-by":"publisher","first-page":"1962","DOI":"10.1007\/s00259-016-3424-3","volume":"43","author":"CH Pfob","year":"2016","unstructured":"Pfob CH, Ziegler S, Graner FP, K\u00f6hner M, Schachoff S, Blechert B, et al. Biodistribution and radiation dosimetry of (68)Ga-PSMA HBED CC-a PSMA specific probe for PET imaging of prostate cancer. Eur J Nucl Med Mol Imaging. 2016;43(11):1962\u201370.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"1646_CR71","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1148\/rg.2018170108","volume":"38","author":"MS Hofman","year":"2018","unstructured":"Hofman MS, Hicks RJ, Maurer T, Eiber M. Prostate-specific membrane antigen PET: clinical utility in prostate cancer, normal patterns, pearls, and pitfalls. Radiographics. 2018;38(1):200\u201317.","journal-title":"Radiographics"},{"issue":"11","key":"1646_CR72","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1097\/MNM.0000000000000566","volume":"37","author":"E Demirci","year":"2016","unstructured":"Demirci E, Sahin OE, Ocak M, Akovali B, Nematyazar J, Kabasakal L. Normal distribution pattern and physiological variants of 68Ga-PSMA-11 PET\/CT imaging. Nucl Med Commun. 2016;37(11):1169\u201379.","journal-title":"Nucl Med Commun"},{"issue":"9","key":"1646_CR73","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1007\/s12149-017-1201-4","volume":"31","author":"RA Werner","year":"2017","unstructured":"Werner RA, Sheikhbahaei S, Jones KM, Javadi MS, Solnes LB, Ross AE, et al. Patterns of uptake of prostate-specific membrane antigen (PSMA)-targeted (18)F-DCFPyL in peripheral ganglia. Ann Nucl Med. 2017;31(9):696\u2013702.","journal-title":"Ann Nucl Med"},{"issue":"9","key":"1646_CR74","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.2967\/jnumed.117.204677","volume":"59","author":"C Rischpler","year":"2018","unstructured":"Rischpler C, Beck TI, Okamoto S, Schlitter AM, Knorr K, Schwaiger M, et al. (68)Ga-PSMA-HBED-CC uptake in cervical, celiac, and sacral ganglia as an important pitfall in prostate cancer PET imaging. J Nucl Med. 2018;59(9):1406\u201311.","journal-title":"J Nucl Med"},{"issue":"10","key":"1646_CR75","doi-asserted-by":"publisher","first-page":"1730","DOI":"10.3390\/diagnostics13101730","volume":"13","author":"F Gossili","year":"2023","unstructured":"Gossili F, Lyngby CG, L\u00f8gager V, Zacho HD. Intense PSMA uptake in a vertebral hemangioma mimicking a solitary bone metastasis in the primary staging of prostate cancer via (68)Ga-PSMA PET\/CT. Diagnostics (Basel). 2023;13(10):1730.","journal-title":"Diagnostics (Basel)"},{"issue":"7","key":"1646_CR76","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.3390\/jcm11071829","volume":"11","author":"S Muselaers","year":"2022","unstructured":"Muselaers S, Erdem S, Bertolo R, Ingels A, Kara \u00d6, Pavan N, et al. PSMA PET\/CT in renal cell carcinoma: an overview of current literature. J Clin Med. 2022;11(7):1829.","journal-title":"J Clin Med"},{"issue":"5","key":"1646_CR77","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1097\/RLU.0000000000001631","volume":"42","author":"C Artigas","year":"2017","unstructured":"Artigas C, Otte FX, Lemort M, van Velthoven R, Flamen P. Vertebral hemangioma mimicking bone metastasis in 68Ga-PSMA ligand PET\/CT. Clin Nucl Med. 2017;42(5):368\u201370.","journal-title":"Clin Nucl Med"},{"issue":"1","key":"1646_CR78","doi-asserted-by":"publisher","first-page":"e69","DOI":"10.1097\/RLU.0000000000001355","volume":"42","author":"S Taneja","year":"2017","unstructured":"Taneja S, Taneja R, Kashyap V, Jha A, Jena A. 68Ga-PSMA uptake in hepatocellular carcinoma. Clin Nucl Med. 2017;42(1):e69\u201370.","journal-title":"Clin Nucl Med"},{"issue":"12","key":"1646_CR79","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1097\/RLU.0000000000001406","volume":"41","author":"R Bilgin","year":"2016","unstructured":"Bilgin R, Erg\u00fcl N, \u00c7ermik TF. Incidental meningioma mimicking metastasis of prostate adenocarcinoma in 68Ga-labeled PSMA ligand PET\/CT. Clin Nucl Med. 2016;41(12):956\u20138.","journal-title":"Clin Nucl Med"},{"issue":"13","key":"1646_CR80","doi-asserted-by":"publisher","first-page":"4483","DOI":"10.1007\/s00259-021-05424-x","volume":"48","author":"H Gr\u00fcnig","year":"2021","unstructured":"Gr\u00fcnig H, Maurer A, Thali Y, Kovacs Z, Strobel K, Burger IA, et al. Focal unspecific bone uptake on [(18)F]-PSMA-1007 PET: a multicenter retrospective evaluation of the distribution, frequency, and quantitative parameters of a potential pitfall in prostate cancer imaging. Eur J Nucl Med Mol Imaging. 2021;48(13):4483\u201394.","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Japanese Journal of Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11604-024-01646-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11604-024-01646-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11604-024-01646-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T12:10:17Z","timestamp":1736424617000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11604-024-01646-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,3]]},"references-count":80,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["1646"],"URL":"https:\/\/doi.org\/10.1007\/s11604-024-01646-9","relation":{},"ISSN":["1867-1071","1867-108X"],"issn-type":[{"value":"1867-1071","type":"print"},{"value":"1867-108X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,3]]},"assertion":[{"value":"4 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}